These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 14641067)
1. Glyoxalase I inhibitors in cancer chemotherapy. Creighton DJ; Zheng ZB; Holewinski R; Hamilton DS; Eiseman JL Biochem Soc Trans; 2003 Dec; 31(Pt 6):1378-82. PubMed ID: 14641067 [TBL] [Abstract][Full Text] [Related]
2. Bivalent transition-state analogue inhibitors of human glyoxalase I. Zheng ZB; Creighton DJ Org Lett; 2003 Dec; 5(25):4855-8. PubMed ID: 14653691 [TBL] [Abstract][Full Text] [Related]
3. Novel bivalent inhibitors with sub-nanomolar affinities towards human glyoxalase I. Sang Y; Shi Q; Mo M; Ni C; Li Z; Liu B; Deng Q; Creighton DJ; Zheng ZB Bioorg Med Chem Lett; 2015 Nov; 25(21):4724-4727. PubMed ID: 26320622 [TBL] [Abstract][Full Text] [Related]
4. An XAS investigation of product and inhibitor complexes of Ni-containing GlxI from Escherichia coli: mechanistic implications. Davidson G; Clugston SL; Honek JF; Maroney MJ Biochemistry; 2001 Apr; 40(15):4569-82. PubMed ID: 11294624 [TBL] [Abstract][Full Text] [Related]
5. Molecular docking and dynamic studies of a potential therapeutic target inhibiting glyoxalase system: Metabolic action of the 3, 3 '- [3- (5-chloro-2-hydroxyphenyl) -3-oxopropane-1, 1-diyl] - Bis-4-hydroxycoumarin leads overexpression of the intracellular level of methylglyoxal and induction of a pro-apoptotic phenomenon in a hepatocellular carcinoma model. Taïbi N; Al-Balas QA; Bekari N; Talhi O; Al Jabal GA; Benali Y; Ameraoui R; Hadjadj M; Taïbi A; Boutaiba ZM; Abou-Mustapha M; Khammar F; Dergal F; Hassaine R; Boukenna L; Bachari K; Soares Silva AM Chem Biol Interact; 2021 Aug; 345():109511. PubMed ID: 33989593 [TBL] [Abstract][Full Text] [Related]
6. Structural variation in bacterial glyoxalase I enzymes: investigation of the metalloenzyme glyoxalase I from Clostridium acetobutylicum. Suttisansanee U; Lau K; Lagishetty S; Rao KN; Swaminathan S; Sauder JM; Burley SK; Honek JF J Biol Chem; 2011 Nov; 286(44):38367-38374. PubMed ID: 21914803 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking. Al-Shar'i NA; Al-Balas QA; Al-Waqfi RA; Hassan MA; Alkhalifa AE; Ayoub NM J Comput Aided Mol Des; 2019 Sep; 33(9):799-815. PubMed ID: 31630312 [TBL] [Abstract][Full Text] [Related]
8. Identification of sequences encoding the detoxification metalloisomerase glyoxalase I in microbial genomes from several pathogenic organisms. Clugston SL; Honek JF J Mol Evol; 2000 May; 50(5):491-5. PubMed ID: 10824093 [TBL] [Abstract][Full Text] [Related]
9. Multiple roles of glyoxalase 1-mediated suppression of methylglyoxal glycation in cancer biology-Involvement in tumour suppression, tumour growth, multidrug resistance and target for chemotherapy. Rabbani N; Xue M; Weickert MO; Thornalley PJ Semin Cancer Biol; 2018 Apr; 49():83-93. PubMed ID: 28506645 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the discovery and development of glyoxalase I inhibitors. Jin T; Zhao L; Wang HP; Huang ML; Yue Y; Lu C; Zheng ZB Bioorg Med Chem; 2020 Feb; 28(4):115243. PubMed ID: 31879183 [TBL] [Abstract][Full Text] [Related]
11. Overproduction and characterization of a dimeric non-zinc glyoxalase I from Escherichia coli: evidence for optimal activation by nickel ions. Clugston SL; Barnard JF; Kinach R; Miedema D; Ruman R; Daub E; Honek JF Biochemistry; 1998 Jun; 37(24):8754-63. PubMed ID: 9628737 [TBL] [Abstract][Full Text] [Related]
12. Modulating glyoxalase I metal selectivity by deletional mutagenesis: underlying structural factors contributing to nickel activation profiles. Suttisansanee U; Ran Y; Mullings KY; Sukdeo N; Honek JF Metallomics; 2015 Apr; 7(4):605-12. PubMed ID: 25557363 [TBL] [Abstract][Full Text] [Related]
13. N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities. Zheng ZB; Zhu G; Tak H; Joseph E; Eiseman JL; Creighton DJ Bioconjug Chem; 2005; 16(3):598-607. PubMed ID: 15898727 [TBL] [Abstract][Full Text] [Related]
14. Novel glyoxalase-I inhibitors possessing a "zinc-binding feature" as potential anticancer agents. Al-Balas QA; Hassan MA; Al-Shar'i NA; Mhaidat NM; Almaaytah AM; Al-Mahasneh FM; Isawi IH Drug Des Devel Ther; 2016; 10():2623-9. PubMed ID: 27574401 [TBL] [Abstract][Full Text] [Related]
15. A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides. Hamilton DS; Kavarana MJ; Sharkey EM; Eiseman JL; Creighton DJ J Med Chem; 1999 May; 42(10):1823-7. PubMed ID: 10346934 [TBL] [Abstract][Full Text] [Related]
16. Investigation of metal binding and activation of Escherichia coli glyoxalase I: kinetic, thermodynamic and mutagenesis studies. Clugston SL; Yajima R; Honek JF Biochem J; 2004 Jan; 377(Pt 2):309-16. PubMed ID: 14556652 [TBL] [Abstract][Full Text] [Related]
17. Inhibition by active site directed covalent modification of human glyoxalase I. Holewinski RJ; Creighton DJ Bioorg Med Chem; 2014 Jul; 22(13):3301-8. PubMed ID: 24856185 [TBL] [Abstract][Full Text] [Related]